Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | GMNN | O75496 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23534464 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL366778 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL599741 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL16401330 | 0.88 | CYP2C19 (0.49) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL16401654 | 0.88 | CYP2C19 (0.49) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL16401332 | 0.88 | CYP2C19 (0.49) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL20680343 | 0.86 | CYP1A2 (0.56) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL19357333 | 0.86 | CYP1A2 (0.56) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL14322640 | 0.85 | CYP1A2 (0.58) | CYP2C19CYP1A2GMNNUSP2POLB | |
| SCHEMBL600897 | 0.85 | CYP1A2 (0.58) | CYP2C19CYP1A2GMNNUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519300-A1 | SHORT APOLIPOPROTEIN E MIMETIC PEPTIDES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2025-03-12 | — | — | EP | claimed |
| EP-4399220-A1 | ANTIVIRAL STRUCTURALLY-STAPLED SARS-COV-2 PEPTIDE- CHOLESTEROL CONJUGATES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3359180-B1 | STABILIZED BCL9 PEPTIDES FOR TREATMENT OF ABERRANT WNT SIGNALING | WNTRX PHARMACEUTICALS INC (US) | 2024-05-15 | — | — | EP | claimed |
| EP-4359432-A2 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-05-01 | — | — | EP | claimed |
| US-20240124529-A1 | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2024-04-18 | — | — | US | claimed |
| US-11865181-B2 | Peptidic materials that traffic efficiently to the cell cytosol and nucleus | YALE UNIVERSITY | 2024-01-09 | — | — | US | claimed |
| CN-113024635-B | Application of stapling peptide compound and pharmaceutical composition thereof | 中国医学科学院药物研究所 | 2023-12-19 | — | — | CN | claimed |
| WO-2023215838-A1 | SHORT APOLIPOPROTEIN E MIMETIC PEPTIDES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-09 | — | — | WO | claimed |
| US-20230265138-A1 | STABILIZED BCL9 PEPTIDES FOR TREATMENT OF ABERRANT WNT SIGNALING | WNTRX PHARMACEUTICALS INC. | 2023-08-24 | — | — | US | claimed |
| US-20230192789-A1 | STRUCTURALLY-STABILIZED AND HDMX-SELECTIVE P53 PEPTIDES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2023-06-22 | — | — | US | claimed |
| EP-3706771-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX Pharmaceuticals Inc. (US) | 2020-09-16 | — | — | EP | claimed |
| US-20200262867-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX PHARMACEUTICALS INC. | 2020-08-20 | — | — | US | claimed |
| WO-2019157131-A1 | CELL-PERMEABLE STAPLED PEPTIDE MODULES FOR CELLULAR DELIVERY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-20190023754-A1 | Stabilized BCL9 Peptides for Treatment of Aberrant WNT Signaling | WNTRX PHARMACEUTICALS INC. | 2019-01-24 | — | — | US | claimed |
| WO-2018112226-A1 | SHARPIN-BASED POLYPEPTIDES AND THEIR USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-06-21 | — | — | WO | claimed |
| US-20180030090-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | US | claimed |
| EP-3256484-A1 | NON-MEMBRANE DISRUPTIVE p53 ACTIVATING STAPLED PEPTIDES | Agency For Science, Technology And Research (SG) | 2017-12-20 | — | — | EP | claimed |
| WO-2017062518-A1 | STABILIZED BCL9 PEPTIDES FOR TREATMENT OF ABERRANT WNT SIGNALING | WNTRX PHARMACEUTICALS INC. (US) | 2017-04-13 | — | — | WO | claimed |
| WO-2016130092-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-18 | — | — | WO | claimed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124529-A1 | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF | ACE2, SARS1, ACE | CYP2C19 4011/4885CYP1A2 4648/4885GMNN 2187/4885 |
| US-20180030090-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | TP53, ANXA3, ANXA2 | CYP2C19 4861/4885CYP1A2 4682/4885GMNN 3239/4885 |
| US-20230192789-A1 | STRUCTURALLY-STABILIZED AND HDMX-SELECTIVE P53 PEPTIDES AND USES THEREOF | TP53, TP53BP1, MDM2 | CYP2C19 4776/4885CYP1A2 4640/4885GMNN 1015/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | CYP2C19 4797/4885CYP1A2 4873/4885GMNN 2931/4885 |
| US-20200262867-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | BCL9, BCL9L, BCL3 | CYP2C19 4413/4885CYP1A2 4758/4885GMNN 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.